{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T20:22:32Z","timestamp":1791404552547,"version":"4.3.3"},"reference-count":143,"publisher":"Elsevier","isbn-type":[{"value":"9780444642776","type":"print"}],"license":[{"start":{"date-parts":[[2019,1,1]],"date-time":"2019-01-01T00:00:00Z","timestamp":1546300800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2019]]},"DOI":"10.1016\/bs.pmch.2018.12.001","type":"book-chapter","created":{"date-parts":[[2019,3,8]],"date-time":"2019-03-08T03:30:50Z","timestamp":1552015850000},"page":"63-117","source":"Crossref","is-referenced-by-count":52,"title":["Amyotrophic lateral sclerosis"],"prefix":"10.1016","author":[{"given":"Klara","family":"Valko","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lukasz","family":"Ciesla","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/bs.pmch.2018.12.001_bb0010","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1016\/j.jalz.2011.03.011","article-title":"Medical and environmental risk factors associated with frontotemporal dementia: a case-control study in a veteran population","volume":"8","author":"Kalkonde","year":"2012","journal-title":"Alzheimers Dement"},{"key":"10.1016\/bs.pmch.2018.12.001_bb0015","doi-asserted-by":"crossref","first-page":"1574","DOI":"10.1136\/jnnp.74.11.1574","article-title":"Medical and environmental risk factors for sporadic frontotemporal dementia: a retrospective case-control study","volume":"74","author":"Rosso","year":"2003","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"10.1016\/bs.pmch.2018.12.001_bb0020","doi-asserted-by":"crossref","first-page":"942","DOI":"10.1016\/S0140-6736(10)61156-7","article-title":"Amyotrophic lateral sclerosis","volume":"377","author":"Kiernan","year":"2011","journal-title":"Lancet (London, England)"},{"key":"10.1016\/bs.pmch.2018.12.001_bb0025","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1385\/NMM:9:1:17","article-title":"Energy intake and amyotrophic lateral sclerosis","volume":"9","author":"Mattson","year":"2007","journal-title":"Neuromolecular Med"},{"key":"10.1016\/bs.pmch.2018.12.001_bb0030","doi-asserted-by":"crossref","first-page":"572","DOI":"10.1038\/ng.132","article-title":"TARDBP mutations in individuals with sporadic and familial amyotrophic lateral sclerosis","volume":"40","author":"Kabashi","year":"2008","journal-title":"Nat Genet"},{"key":"10.1016\/bs.pmch.2018.12.001_bb0035","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1007\/s11910-003-0041-x","article-title":"Recent advances in amyotrophic lateral sclerosis research","volume":"3","author":"Przedborski","year":"2003","journal-title":"Curr Neurol Neurosci Rep"},{"key":"10.1016\/bs.pmch.2018.12.001_bb0040","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1097\/00019052-200008000-00006","article-title":"Recent advances in amyotrophic lateral sclerosis","volume":"13","author":"Al-Chalabi","year":"2000","journal-title":"Curr Opin Neurol"},{"key":"10.1016\/bs.pmch.2018.12.001_bb0045","doi-asserted-by":"crossref","first-page":"1267","DOI":"10.1517\/13543784.2012.703178","article-title":"Clinical utility of neuroprotective agents in neurodegenerative diseases: current status of drug development for Alzheimer's, Parkinson's and Huntington's diseases, and amyotrophic lateral sclerosis","volume":"21","author":"Dunkel","year":"2012","journal-title":"Expert Opin Investig Drugs"},{"key":"10.1016\/bs.pmch.2018.12.001_bb0050","first-page":"25","article-title":"Edaravone (Radicava): a novel neuroprotective agent for the treatment of amyotrophic lateral sclerosis","volume":"43","author":"Cruz","year":"2018","journal-title":"Pharmacol Ther"},{"key":"10.1016\/bs.pmch.2018.12.001_bb0055","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1016\/S1474-4422(17)30115-1","article-title":"Safety and efficacy of edaravone in well defined patients with amyotrophic lateral sclerosis: a randomised, double-blind, placebo-controlled trial","volume":"16","author":"Abe","year":"2017","journal-title":"Lancet Neurol"},{"key":"10.1016\/bs.pmch.2018.12.001_bb0060","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1038\/nature05292","article-title":"Mitochondrial dysfunction and oxidative stress in neurodegenerative diseases","volume":"443","author":"Lin","year":"2006","journal-title":"Nature"},{"key":"10.1016\/bs.pmch.2018.12.001_bb0065","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1016\/j.neuron.2012.08.016","article-title":"Neural mechanisms of stress resilience and vulnerability","volume":"75","author":"Franklin","year":"2012","journal-title":"Neuron"},{"key":"10.1016\/bs.pmch.2018.12.001_bb0070","doi-asserted-by":"crossref","first-page":"506","DOI":"10.1086\/301968","article-title":"Assignment of the disease locus for lethal congenital contracture syndrome to a restricted region of chromosome 9q34, by genome scan using five affected individuals","volume":"63","author":"M\u00e4kel\u00e4-Bengs","year":"1998","journal-title":"Am J Hum Genet"},{"key":"10.1016\/bs.pmch.2018.12.001_bb0075","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1007\/s100480050052","article-title":"Linkage of a commoner form of recessive amyotrophic lateral sclerosis to chromosome 15q15-q22 markers","volume":"2","author":"Hentati","year":"1998","journal-title":"Neurogenetics"},{"key":"10.1016\/bs.pmch.2018.12.001_bb0080","doi-asserted-by":"crossref","first-page":"887","DOI":"10.1007\/s00401-017-1687-9","article-title":"Motor neuron intrinsic and extrinsic mechanisms contribute to the pathogenesis of FUS-associated amyotrophic lateral sclerosis","volume":"133","author":"Scekic-Zahirovic","year":"2017","journal-title":"Acta Neuropathol"},{"key":"10.1016\/bs.pmch.2018.12.001_bb0085","doi-asserted-by":"crossref","first-page":"812","DOI":"10.1002\/humu.22319","article-title":"TARDBP and FUS mutations associated with amyotrophic lateral sclerosis: summary and update","volume":"34","author":"Lattante","year":"2013","journal-title":"Hum Mutat"},{"key":"10.1016\/bs.pmch.2018.12.001_bb0090","doi-asserted-by":"crossref","first-page":"2415","DOI":"10.1046\/j.1471-4159.1999.0722415.x","article-title":"Inducible nitric oxide synthase up-regulation in a transgenic mouse model of familial amyotrophic lateral sclerosis","volume":"72","author":"Almer","year":"1999","journal-title":"J Neurochem"},{"key":"10.1016\/bs.pmch.2018.12.001_bb0095","doi-asserted-by":"crossref","first-page":"1175","DOI":"10.1046\/j.1471-4159.1999.0731175.x","article-title":"Aberrant copper chemistry as a major mediator of oxidative stress in a human cellular model of amyotrophic lateral sclerosis","volume":"73","author":"Gabbianelli","year":"1999","journal-title":"J Neurochem"},{"key":"10.1016\/bs.pmch.2018.12.001_bb0100","doi-asserted-by":"crossref","first-page":"8501","DOI":"10.1523\/JNEUROSCI.1081-12.2012","article-title":"Peripherin is a subunit of peripheral nerve neurofilaments: implications for differential vulnerability of CNS and peripheral nervous system axons","volume":"32","author":"Yuan","year":"2012","journal-title":"J Neurosci"},{"key":"10.1016\/bs.pmch.2018.12.001_bb0105","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1146\/annurev-pharmtox-011112-140320","article-title":"Role of nrfe in oxidative stress and toxicity","volume":"53","author":"Ma","year":"2013","journal-title":"Annu Rev Pharmacol Toxicol"},{"key":"10.1016\/bs.pmch.2018.12.001_bb0110","first-page":"13574","article-title":"Nrf2 activation in astrocytes protects against neurodegeneration in mouse models of familial amyotrophic lateral sclerosis","volume":"28","author":"Vargas","year":"2010","journal-title":"Annu Rev Neurosci"},{"key":"10.1016\/bs.pmch.2018.12.001_bb0115","doi-asserted-by":"crossref","first-page":"2933","DOI":"10.1073\/pnas.0813361106","article-title":"Nrf2-mediated neuroprotection in the MPTP mouse model of Parkinson's disease: critical role for the astrocyte","volume":"106","author":"Chen","year":"2009","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/bs.pmch.2018.12.001_bb0120","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1016\/j.bbadis.2012.11.013","article-title":"Role of the N-methyl-d-aspartate receptors complex in amyotrophic lateral sclerosis","volume":"1832","author":"Spalloni","year":"2013","journal-title":"Biochim Biophys Acta"},{"key":"10.1016\/bs.pmch.2018.12.001_bb0125","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1016\/S0896-6273(00)80997-6","article-title":"Aberrant RNA processing in a neurodegenerative disease: the cause for absent EAAT2, a glutamate transporter, in amyotrophic lateral sclerosis","volume":"20","author":"Lin","year":"1998","journal-title":"Neuron"},{"key":"10.1016\/bs.pmch.2018.12.001_bb0130","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1016\/S0304-3940(97)00973-7","article-title":"Alternative splicing of the glutamate transporter EAAT2 (GLT-1)","volume":"241","author":"Meyer","year":"1998","journal-title":"Neurosci Lett"},{"key":"10.1016\/bs.pmch.2018.12.001_bb0135","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1002\/1531-8249(199911)46:5<787::AID-ANA17>3.0.CO;2-8","article-title":"Mitochondrial enzyme activity in amyotrophic lateral sclerosis: implications for the role of mitochondria in neuronal cell death","volume":"46","author":"Borthwick","year":"1999","journal-title":"Ann Neurol"},{"key":"10.1016\/bs.pmch.2018.12.001_bb0140","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1016\/0022-510X(84)90154-0","article-title":"Insulin resistance in amyotrophic lateral sclerosis","volume":"63","author":"Reyes","year":"1984","journal-title":"J Neurol Sci"},{"key":"10.1016\/bs.pmch.2018.12.001_bb0145","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1038\/nrn3209","article-title":"The many faces of insulin-like peptide signalling in the brain","volume":"13","author":"Fernandez","year":"2012","journal-title":"Nat Rev Neurosci"},{"key":"10.1016\/bs.pmch.2018.12.001_bb0150","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1016\/0169-328X(96)00081-2","article-title":"Distribution and levels of insulin-like growth factor (IGF-I and IGF-II) and insulin receptor binding sites in the spinal cords of amyotrophic lateral sclerosis (ALS) patients","volume":"41","author":"Dor\u00e9","year":"1996","journal-title":"Brain Res Mol Brain Res"},{"key":"10.1016\/bs.pmch.2018.12.001_bb0155","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1006\/exnr.1993.1177","article-title":"Insulin-like growth factor-I: potential for treatment of motor neuronal disorders","volume":"124","author":"Lewis","year":"1993","journal-title":"Exp Neurol"},{"key":"10.1016\/bs.pmch.2018.12.001_bb0160","doi-asserted-by":"crossref","first-page":"1578","DOI":"10.1002\/neu.480241203","article-title":"Insulin-like growth factors: putative muscle-derived trophic agents that promote motoneuron survival","volume":"24","author":"Neff","year":"1993","journal-title":"J Neurobiol"},{"key":"10.1016\/bs.pmch.2018.12.001_bb0165","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3389\/fncel.2014.00061","article-title":"Trophic factors as modulators of motor neuron physiology and survival: implications for ALS therapy","volume":"8","author":"Tovar-y-Romo","year":"2014","journal-title":"Front Cell Neurosci"},{"key":"10.1016\/bs.pmch.2018.12.001_bb0170","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1002\/jez.1401110308","article-title":"Proliferation, differentiation and degeneration in the spinal ganglia of the chick embryo under normal and experimental conditions","volume":"111","author":"Hamburger","year":"1949","journal-title":"J Exp Zool"},{"key":"10.1016\/bs.pmch.2018.12.001_bb0175","doi-asserted-by":"crossref","first-page":"1154","DOI":"10.1126\/science.3306916","article-title":"The nerve growth factor 35 years later","volume":"237","author":"Levi-montalcini","year":"1987","journal-title":"Science"},{"key":"10.1016\/bs.pmch.2018.12.001_bb0180","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1146\/annurev.cb.07.110191.003311","article-title":"Mechanisms and functions of cell death","volume":"7","author":"Ellis","year":"1991","journal-title":"Annu Rev Cell Biol"},{"key":"10.1016\/bs.pmch.2018.12.001_bb0185","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1002\/ana.410100602","article-title":"A unifying hypothesis for the cause of amyotrophic lateral sclerosis, parkinsonism, and Alzheimer disease","volume":"10","author":"Appel","year":"1981","journal-title":"Ann Neurol"},{"key":"10.1016\/bs.pmch.2018.12.001_bb0190","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1007\/s00441-004-0920-8","article-title":"Factors promoting survival of mesencephalic dopaminergic neurons","volume":"318","author":"Krieglstein","year":"2004","journal-title":"Cell Tissue Res"},{"key":"10.1016\/bs.pmch.2018.12.001_bb0195","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/j.tem.2013.10.006","article-title":"BDNF mediates adaptive brain and body responses to energetic challenges","volume":"25","author":"Marosi","year":"2014","journal-title":"Trends Endocrinol Metab"},{"key":"10.1016\/bs.pmch.2018.12.001_bb0200","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1002\/aja.1001020303","article-title":"Regression versus peripheral control of differentiation in motor hypoplasia","volume":"102","author":"Hamburger","year":"1958","journal-title":"Am J Anat"},{"key":"10.1016\/bs.pmch.2018.12.001_bb0205","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1073\/pnas.46.3.302","article-title":"Purification of a nerve-growth promoting protein from the mouse salivary gland and its neuro-cytotoxic antiserum","volume":"46","author":"Cohen","year":"1960","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/bs.pmch.2018.12.001_bb0210","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/0006-8993(74)90536-8","article-title":"The retrograde axonal transport of nerve growth factor","volume":"68","author":"Hendry","year":"1974","journal-title":"Brain Res"},{"key":"10.1016\/bs.pmch.2018.12.001_bb0215","doi-asserted-by":"crossref","first-page":"1093","DOI":"10.1017\/S095252380000691X","article-title":"Nerve growth factor (NGF) uptake and transport following injection in the developing rat visual cortex","volume":"11","author":"Domenici","year":"1994","journal-title":"Vis Neurosci"},{"key":"10.1016\/bs.pmch.2018.12.001_bb0220","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1016\/0896-6273(90)90166-D","article-title":"Brain-derived neurotrophic factor increases survival and differentiated functions of rat septal cholinergic neurons in culture","volume":"5","author":"Alderson","year":"1990","journal-title":"Neuron"},{"key":"10.1016\/bs.pmch.2018.12.001_bb0225","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1016\/j.brainres.2008.08.053","article-title":"Motoneuronotrophic factor analog GM6 reduces infarct volume and behavioral deficits following transient ischemia in the mouse","volume":"1238","author":"Yu","year":"2008","journal-title":"Brain Res"},{"key":"10.1016\/bs.pmch.2018.12.001_bb0230","series-title":"MNTF differentiation and growth of stem cells","author":"Deshpande","year":"2015"},{"key":"10.1016\/bs.pmch.2018.12.001_bb0235","series-title":"Methods of treating neuronal disorders using MNTF peptides and analogs","author":"Kindy","year":"2014"},{"key":"10.1016\/bs.pmch.2018.12.001_bb0240","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1016\/j.neuroscience.2011.12.025","article-title":"Caffeic acid phenethyl ester extends survival of a mouse model of amyotrophic lateral sclerosis","volume":"205","author":"Fontanilla","year":"2012","journal-title":"Neuroscience"},{"key":"10.1016\/bs.pmch.2018.12.001_bb0245","doi-asserted-by":"crossref","first-page":"3057","DOI":"10.1007\/s00018-004-4268-8","article-title":"Neurofilament proteins in neurodegenerative diseases","volume":"61","author":"Liu","year":"2004","journal-title":"Cell Mol Life Sci"},{"key":"10.1016\/bs.pmch.2018.12.001_bb0250","doi-asserted-by":"crossref","first-page":"1179","DOI":"10.1021\/ml500404b","article-title":"Treatment of amyotrophic lateral sclerosis: lessons learned from many failures","volume":"5","author":"\u00d6zdinler","year":"2014","journal-title":"ACS Med Chem Lett"},{"key":"10.1016\/bs.pmch.2018.12.001_bb0255","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1038\/507423a","article-title":"Make mouse studies work","volume":"507","author":"Perrin","year":"2014","journal-title":"Nature"},{"key":"10.1016\/bs.pmch.2018.12.001_bb0260","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1016\/j.drudis.2013.10.014","article-title":"Moving forward in clinical trials for ALS: motor neurons lead the way please","volume":"19","author":"Genc","year":"2014","journal-title":"Drug Discov Today"},{"key":"10.1016\/bs.pmch.2018.12.001_bb0265","doi-asserted-by":"crossref","first-page":"321","DOI":"10.2174\/138920212800793366","article-title":"Identification of pharmacological targets in amyotrophic lateral sclerosis through genomic analysis of deregulated genes and pathways","volume":"13","author":"Paratore","year":"2012","journal-title":"Curr Genomics"},{"key":"10.1016\/bs.pmch.2018.12.001_bb0270","series-title":"Treatment of amyotrophic lateral sclerosis with nimesulide","author":"Pasinetti","year":"2006"},{"key":"10.1016\/bs.pmch.2018.12.001_bb0275","series-title":"Diazoxide for use in the treatment of amyotrophic lateral sclerosis (ALS)","author":"Puliese","year":"2012"},{"key":"10.1016\/bs.pmch.2018.12.001_bb0280","doi-asserted-by":"crossref","first-page":"621","DOI":"10.2174\/138945007780618472","article-title":"Pathologically-activated therapeutics for neuroprotection: mechanism of NMDA receptor block by memantine and S-nitrosylation","volume":"8","author":"Lipton","year":"2007","journal-title":"Curr Drug Targets"},{"key":"10.1016\/bs.pmch.2018.12.001_bb0285","doi-asserted-by":"crossref","first-page":"1002","DOI":"10.1590\/S0100-879X2009001100002","article-title":"Glutamate-N-methyl-d-aspartate receptor modulation and minocycline for the treatment of patients with schizophrenia: an update","volume":"42","author":"Chaves","year":"2009","journal-title":"Braz J Med Biol Res"},{"key":"10.1016\/bs.pmch.2018.12.001_bb0290","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1007\/s00213-004-2065-6","article-title":"Therapeutic potential of positive AMPA modulators and their relationship to AMPA receptor subunits. A review of preclinical data","volume":"179","author":"Black","year":"2005","journal-title":"Psychopharmacology (Berl)"},{"key":"10.1016\/bs.pmch.2018.12.001_bb0295","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1038\/417074a","article-title":"Minocycline inhibits cytochrome c release and delays progression of amyotrophic lateral sclerosis in mice","volume":"417","author":"Zhu","year":"2002","journal-title":"Nature"},{"key":"10.1016\/bs.pmch.2018.12.001_bb0300","series-title":"Therapeutic agent for amyotrophic lateral sclerosis","author":"Ikeda","year":"2011"},{"key":"10.1016\/bs.pmch.2018.12.001_bb0305","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1080\/17482960701791234","article-title":"R(+) pramipexole as a mitochondrially focused neuroprotectant: initial early phase studies in ALS","volume":"9","author":"Wang","year":"2008","journal-title":"Amyotroph Lateral Scler"},{"key":"10.1016\/bs.pmch.2018.12.001_bb0310","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1016\/S1474-4422(17)30163-1","article-title":"Edaravone: a new treatment for ALS on the horizon?","volume":"16","author":"Hardiman","year":"2017","journal-title":"Lancet Neurol"},{"key":"10.1016\/bs.pmch.2018.12.001_bb0315","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/0005-2728(96)00074-6","article-title":"Differential effects of creatine depletion on the regulation of enzyme activities and on creatine-stimulated mitochondrial respiration in skeletal muscle, heart, and brain","volume":"1276","author":"O'Gorman","year":"1996","journal-title":"Biochim Biophys Acta"},{"key":"10.1016\/bs.pmch.2018.12.001_bb0320","doi-asserted-by":"crossref","first-page":"576","DOI":"10.1046\/j.1471-4159.2003.02160.x","article-title":"Additive neuroprotective effects of creatine and cyclooxygenase 2 inhibitors in a transgenic mouse model of amyotrophic lateral sclerosis","volume":"88","author":"Klivenyi","year":"2004","journal-title":"J Neurochem"},{"key":"10.1016\/bs.pmch.2018.12.001_bb0325","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1080\/17482960802028890","article-title":"Creatine monohydrate in ALS: effects on strength, fatigue, respiratory status and ALSFRS","volume":"9","author":"Rosenfeld","year":"2008","journal-title":"Amyotroph Lateral Scler"},{"key":"10.1016\/bs.pmch.2018.12.001_bb0330","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1111\/j.1600-079X.2006.00377.x","article-title":"Reduced oxidative damage in ALS by high-dose enteral melatonin treatment","volume":"41","author":"Weishaupt","year":"2006","journal-title":"J Pineal Res"},{"key":"10.1016\/bs.pmch.2018.12.001_bb0335","first-page":"345","article-title":"The anti-apoptotic activity of melatonin in neurodegenerative diseases","volume":"15","author":"Wang","year":"2010","journal-title":"Stroke"},{"key":"10.1016\/bs.pmch.2018.12.001_bb0340","doi-asserted-by":"crossref","first-page":"4064","DOI":"10.1242\/jcs.153346","article-title":"Divergent and convergent roles for kinases and phosphatases in neurofilament dynamics","volume":"127","author":"Lee","year":"2014","journal-title":"J Cell Sci"},{"key":"10.1016\/bs.pmch.2018.12.001_bb0345","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1002\/ana.21425","article-title":"Phosphorylated TDP-43 in frontotemporal lobar degeneration and amyotrophic lateral sclerosis","volume":"64","author":"Hasegawa","year":"2008","journal-title":"Ann Neurol"},{"key":"10.1016\/bs.pmch.2018.12.001_bb0350","doi-asserted-by":"crossref","first-page":"2755","DOI":"10.1021\/jm500065f","article-title":"Protein kinase CK-1 inhibitors as new potential drugs for amyotrophic lateral sclerosis","volume":"57","author":"Salado","year":"2014","journal-title":"J Med Chem"},{"key":"10.1016\/bs.pmch.2018.12.001_bb0355","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1212\/01.wnl.0000223353.34006.54","article-title":"Neuroprotective agents for clinical trials in ALS: a systematic assessment","volume":"67","author":"Traynor","year":"2006","journal-title":"Neurology"},{"key":"10.1016\/bs.pmch.2018.12.001_bb0360","doi-asserted-by":"crossref","first-page":"39","DOI":"10.4081\/ni.2015.5885","article-title":"Amyotrophic lateral sclerosis: new perpectives and update","volume":"7","author":"Orsini","year":"2015","journal-title":"Neurol Int"},{"key":"10.1016\/bs.pmch.2018.12.001_bb0365","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1080\/14660820510037872","article-title":"Excitotoxicity and ALS: what is uniques about the AMPA receptors expressed on spinal motor neurons?","volume":"6","author":"Kawahara","year":"2005","journal-title":"Amyotroph Lateral Scler"},{"key":"10.1016\/bs.pmch.2018.12.001_bb0370","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1007\/s00109-004-0599-z","article-title":"Deficient RNA editing of GluR2 and neuronal death in amyotropic lateral sclerosis","volume":"83","author":"Kwak","year":"2005","journal-title":"J Mol Med"},{"key":"10.1016\/bs.pmch.2018.12.001_bb0375","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1111\/j.1471-4159.2008.05595.x","article-title":"Late stage treatment with arimoclomol delays disease progression and prevents protein aggregation in the SOD1G93Amouse model of ALS","volume":"107","author":"Kalmar","year":"2008","journal-title":"J Neurochem"},{"key":"10.1016\/bs.pmch.2018.12.001_bb0380","doi-asserted-by":"crossref","first-page":"500","DOI":"10.1016\/j.apsb.2015.07.007","article-title":"Mechanism-based design of 2,3-benzodiazepine inhibitors for AMPA receptors","volume":"5","author":"Niu","year":"2015","journal-title":"Acta Pharm Sin B"},{"key":"10.1016\/bs.pmch.2018.12.001_bb0385","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1021\/cn400193u","article-title":"Mechanism and site of inhibition of AMPA receptors: pairing a thiadiazole with a 2,3-benzodiazepine scaffold","volume":"5","author":"Wang","year":"2014","journal-title":"ACS Chem Neurosci"},{"key":"10.1016\/bs.pmch.2018.12.001_bb0390","first-page":"156","article-title":"Beta-lactam antibiotic offers neuroprotection in a spinal muscular atrophy model by multiple mechanisms: Experimental Neurology 2011; 229: 214-225","volume":"18","author":"Nizzardo","year":"2011","journal-title":"Ann Neurosci"},{"key":"10.1016\/bs.pmch.2018.12.001_bb0395","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1038\/nature03180","article-title":"\u03b2-Lactam antibiotics offer neuroprotection by increasing glutamate transporter expression","volume":"433","author":"Rothstein","year":"2005","journal-title":"Nature"},{"key":"10.1016\/bs.pmch.2018.12.001_bb0400","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1212\/WNL.61.4.456","article-title":"A randomized, placebo-controlled trial of topiramate in amyotrophic lateral sclerosis","volume":"61","author":"Cudkowicz","year":"2003","journal-title":"Neurology"},{"key":"10.1016\/bs.pmch.2018.12.001_bb0405","doi-asserted-by":"crossref","first-page":"2188","DOI":"10.1046\/j.1460-9568.2003.02950.x","article-title":"Generation and phenotypic analysis of sigma receptor type I (\u03c31) knockout mice","volume":"18","author":"Langa","year":"2003","journal-title":"Eur J Neurosci"},{"key":"10.1016\/bs.pmch.2018.12.001_bb0410","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1002\/ana.22274","article-title":"Sigma nonopioid intracellular receptor 1 mutations cause frontotemporal lobar degeneration-motor neuron disease","volume":"68","author":"Luty","year":"2010","journal-title":"Ann Neurol"},{"key":"10.1016\/bs.pmch.2018.12.001_bb0415","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1016\/j.neulet.2013.12.005","article-title":"SA4503, a sigma-1 receptor agonist, suppresses motor neuron damage in in vitro and in vivo amyotrophic lateral sclerosis models","volume":"559","author":"Ono","year":"2014","journal-title":"Neurosci Lett"},{"key":"10.1016\/bs.pmch.2018.12.001_bb0420","first-page":"568","article-title":"Olesoxime, a cholesterol-like neuroprotectant for the potential treatment of amyotrophic lateral sclerosis","volume":"13","author":"Martin","year":"2010","journal-title":"IDrugs"},{"key":"10.1016\/bs.pmch.2018.12.001_bb0425","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1124\/jpet.107.123000","article-title":"Identification and characterization of cholest-4-en-3-one, oxime (TRO19622), a novel drug candidate for amyotrophic lateral sclerosis","volume":"322","author":"Bordet","year":"2007","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1016\/bs.pmch.2018.12.001_bb0430","doi-asserted-by":"crossref","first-page":"1","DOI":"10.2165\/11586000-000000000-00000","article-title":"Amyotrophic lateral sclerosis: pathophysiology, diagnosis and management","volume":"25","author":"Gordon","year":"2011","journal-title":"CNS Drugs"},{"key":"10.1016\/bs.pmch.2018.12.001_bb0435","doi-asserted-by":"crossref","DOI":"10.1038\/npre.2010.5237.1","article-title":"AAD-2004, a potent spin trapping molecule and microsomal prostaglandin E synthase-1 inhibitor, shows safety and efficacy in a mouse model of ALS","author":"Shin","year":"2010"},{"key":"10.1016\/bs.pmch.2018.12.001_bb0440","doi-asserted-by":"crossref","first-page":"762","DOI":"10.1007\/s13311-016-0508-5","article-title":"Enhanced bulbar function in amyotrophic lateral sclerosis: the Nuedexta treatment trial","volume":"14","author":"Smith","year":"2017","journal-title":"Neurotherapeutics"},{"key":"10.1016\/bs.pmch.2018.12.001_bb0445","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1212\/01.wnl.0000191326.40772.62","article-title":"Pentoxifylline in ALS A double-blind, randomized, multicenter, placebo-controlled trial","volume":"66","author":"Meininger","year":"2006","journal-title":"Neurology"},{"key":"10.1016\/bs.pmch.2018.12.001_bb0450","doi-asserted-by":"crossref","first-page":"2467","DOI":"10.1523\/JNEUROSCI.5253-05.2006","article-title":"Thalidomide and lenalidomide extend survival in a transgenic mouse model of amyotrophic lateral sclerosis","volume":"26","author":"Kiaei","year":"2006","journal-title":"J Neurosci"},{"key":"10.1016\/bs.pmch.2018.12.001_bb0455","doi-asserted-by":"crossref","first-page":"393","DOI":"10.3109\/17482960802709416","article-title":"Efficacy of thalidomide for the treatment of amyotrophic lateral sclerosis: a phase II open label clinical trial","volume":"10","author":"Stommel","year":"2009","journal-title":"Amyotroph Lateral Scler"},{"key":"10.1016\/bs.pmch.2018.12.001_bb0460","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1007\/s00415-008-0756-3","article-title":"Thalidomide causes sinus bradycardia in ALS","volume":"255","author":"Meyer","year":"2008","journal-title":"J Neurol"},{"key":"10.1016\/bs.pmch.2018.12.001_bb0465","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1016\/j.expneurol.2004.10.007","article-title":"Peroxisome proliferator-activated receptor-gamma agonist extends survival in transgenic mouse model of amyotrophic lateral sclerosis","volume":"191","author":"Kiaei","year":"2005","journal-title":"Exp Neurol"},{"key":"10.1016\/bs.pmch.2018.12.001_bb0470","doi-asserted-by":"crossref","first-page":"6920","DOI":"10.1523\/JNEUROSCI.22-16-06920.2002","article-title":"Neuroprotective effects of glial cell line-derived neurotrophic factor mediated by an adeno-associated virus vector in a transgenic animal model of amyotrophic lateral sclerosis","volume":"22","author":"Wang","year":"2002","journal-title":"J Neurosci"},{"key":"10.1016\/bs.pmch.2018.12.001_bb0475","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/j.neuron.2006.02.020","article-title":"Cooperation between GDNF\/Ret and ephrinA\/EphA4 signals for motor-axon pathway selection in the limb","volume":"50","author":"Kramer","year":"2006","journal-title":"Neuron"},{"key":"10.1016\/bs.pmch.2018.12.001_bb0480","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1080\/08977190410001723308","article-title":"Brain-derived neurotrophic factor","volume":"22","author":"Binder","year":"2004","journal-title":"Growth Factors"},{"key":"10.1016\/bs.pmch.2018.12.001_bb0485","doi-asserted-by":"crossref","first-page":"8854","DOI":"10.1523\/JNEUROSCI.23-26-08854.2003","article-title":"Cardiotrophin-like cytokine\/cytokine-like factor 1 is an essential trophic factor for lumbar and facial motoneurons in vivo","volume":"23","author":"Forger","year":"2003","journal-title":"J Neurosci"},{"key":"10.1016\/bs.pmch.2018.12.001_bb0490","doi-asserted-by":"crossref","first-page":"2169","DOI":"10.1038\/sj.onc.1201380","article-title":"p38 MAP kinase activation by vascular endothelial growth factor mediates actin reorganization and cell migration in human endothelial cells","volume":"15","author":"Rousseau","year":"1997","journal-title":"Oncogene"},{"key":"10.1016\/bs.pmch.2018.12.001_bb0495","doi-asserted-by":"crossref","first-page":"3335","DOI":"10.1093\/brain\/awn243","article-title":"Granulocyte-colony stimulating factor improves outcome in a mouse model of amyotrophic lateral sclerosis","volume":"131","author":"Pitzer","year":"2008","journal-title":"Brain"},{"key":"10.1016\/bs.pmch.2018.12.001_bb0500","doi-asserted-by":"crossref","first-page":"6537","DOI":"10.1523\/JNEUROSCI.22-15-06537.2002","article-title":"Overexpression of HGF retards disease progression and prolongs life span in a transgenic mouse model of ALS","volume":"22","author":"Sun","year":"2002","journal-title":"J Neurosci"},{"key":"10.1016\/bs.pmch.2018.12.001_bb0505","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1016\/j.neures.2007.08.017","article-title":"Hepatocyte growth factor (HGF) attenuates gliosis and motoneuronal degeneration in the brainstem motor nuclei of a transgenic mouse model of ALS","volume":"59","author":"Kadoyama","year":"2007","journal-title":"Neurosci Res"},{"key":"10.1016\/bs.pmch.2018.12.001_bb0510","doi-asserted-by":"crossref","first-page":"1621","DOI":"10.1212\/WNL.49.6.1621","article-title":"Effect of recombinant human insulin-like growth factor-I on progression of ALS. A placebo-controlled study. The North America ALS\/IgF-I study group","volume":"49","author":"Lai","year":"1997","journal-title":"Neurology"},{"key":"10.1016\/bs.pmch.2018.12.001_bb0515","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1080\/17482960802160370","article-title":"Insulin-like growth factor-I for the treatment of amyotrophic lateral sclerosis","volume":"10","author":"A Sakowski","year":"2009","journal-title":"Amyotroph Lateral Scler"},{"key":"10.1016\/bs.pmch.2018.12.001_bb0520","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1016\/j.expneurol.2008.10.014","article-title":"Mechano-growth factor, an IGF-I splice variant, rescues motoneurons and improves muscle function in SOD1G93Amice","volume":"215","author":"Riddoch-Contreras","year":"2009","journal-title":"Exp Neurol"},{"key":"10.1016\/bs.pmch.2018.12.001_bb0525","doi-asserted-by":"crossref","first-page":"913","DOI":"10.1097\/nen.0b013e3181567c16","article-title":"Vascular endothelial growth factor prevents paralysis and motoneuron death in a rat model of excitotoxic spinal cord neurodegeneration","volume":"66","author":"Tovar-Y-Romo","year":"2007","journal-title":"J Neuropathol Exp Neurol"},{"key":"10.1016\/bs.pmch.2018.12.001_bb0530","series-title":"MNTF peptides and composition and method of use","author":"Ko","year":"2007"},{"key":"10.1016\/bs.pmch.2018.12.001_bb0535","series-title":"MNTF differentiation and growth of stem cell","author":"Ko","year":"2015"},{"key":"10.1016\/bs.pmch.2018.12.001_bb0540","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1186\/s40035-018-0135-7","article-title":"GM604 regulates developmental neurogenesis pathways and the expression of genes associated with amyotrophic lateral sclerosis","volume":"7","author":"Swindell","year":"2018","journal-title":"Transl Neurodegener"},{"key":"10.1016\/bs.pmch.2018.12.001_bb0545","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3389\/fendo.2014.00161","article-title":"Insulin in the brain: its pathophysiological implications for states related with central insulin resistance, type 2 diabetes and Alzheimer's disease","volume":"5","author":"Bl\u00e1zquez","year":"2014","journal-title":"Front Endocrinol (Lausanne)"},{"key":"10.1016\/bs.pmch.2018.12.001_bb0550","doi-asserted-by":"crossref","first-page":"162","DOI":"10.5599\/admet.544","article-title":"Application of biomimetic HPLC to estimate lipophilicity, protein and phospholipid binding of potential peptide therapeutics","volume":"6","author":"Valko","year":"2018","journal-title":"ADMET DMPK"},{"key":"10.1016\/bs.pmch.2018.12.001_bb0555","doi-asserted-by":"crossref","first-page":"176","DOI":"10.5599\/admet.547","article-title":"In vitro biomimetic HPLC and in vivo characterisation of GM6, an endogenous regulator peptide drug candidate for amyotrophic lateral sclerosis","volume":"6","author":"Valko","year":"2018","journal-title":"ADMET DMPK"},{"key":"10.1016\/bs.pmch.2018.12.001_bb0560","doi-asserted-by":"crossref","first-page":"6958","DOI":"10.1021\/jm050957i","article-title":"Estimation of volume of distribution in humans from HPLC measurements of human serum albumin binding and immobilized artificial membrane partitioning","volume":"49","author":"Hollosy","year":"2006","journal-title":"J Med Chem"},{"key":"10.1016\/bs.pmch.2018.12.001_bb0565","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1002\/bies.200800210","article-title":"Ligand-induced activation of the insulin receptor: a multi-step process involving structural changes in both the ligand and the receptor","volume":"31","author":"Ward","year":"2009","journal-title":"Bioessays"},{"key":"10.1016\/bs.pmch.2018.12.001_bb0570","doi-asserted-by":"crossref","first-page":"230","DOI":"10.12688\/f1000research.10519.1","article-title":"A phase 2A randomized, double-blind, placebo-controlled pilot trial of GM604 in patients with Amyotrophic Lateral Sclerosis (ALS Protocol GALS-001) and a single compassionate patient treatment (Protocol GALS-C)","volume":"6","author":"Kindy","year":"2017","journal-title":"F1000Research"},{"key":"10.1016\/bs.pmch.2018.12.001_bb0575","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1016\/j.ejpb.2004.02.018","article-title":"Chances and pitfalls of cell penetrating peptides for cellular drug delivery","volume":"58","author":"Trehin","year":"2004","journal-title":"Eur J Pharm Biopharm"},{"key":"10.1016\/bs.pmch.2018.12.001_bb0580","doi-asserted-by":"crossref","first-page":"850","DOI":"10.1016\/j.drudis.2012.03.002","article-title":"Cell-penetrating peptides: classes, origin, and current landscape","volume":"17","author":"Milletti","year":"2012","journal-title":"Drug Discov Today"},{"key":"10.1016\/bs.pmch.2018.12.001_bb0585","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1016\/S0168-3659(03)00008-7","article-title":"Reversible lipidization for the oral delivery of salmon calcitonin","volume":"88","author":"Wang","year":"2003","journal-title":"J Control Release"},{"key":"10.1016\/bs.pmch.2018.12.001_bb0590","first-page":"1","article-title":"Protein\u2013 and peptide\u2013drug conjugates: an emerging drug delivery technology","volume":"5","author":"Vhora","year":"2015","journal-title":"Adv Protein Chem Struct Biol"},{"key":"10.1016\/bs.pmch.2018.12.001_bb0595","doi-asserted-by":"crossref","first-page":"2557","DOI":"10.1002\/jps.22054","article-title":"Delivery of therapeutic proteins","volume":"99","author":"Pisal","year":"2010","journal-title":"J Pharm Sci"},{"key":"10.1016\/bs.pmch.2018.12.001_bb0600","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1016\/S0092-8674(02)00835-8","article-title":"Directed differentiation of embryonic stem cells into motor neurons","volume":"110","author":"Wichterle","year":"2002","journal-title":"Cell"},{"key":"10.1016\/bs.pmch.2018.12.001_bb0605","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0042614","article-title":"Human neural stem cell replacement therapy for amyotrophic lateral sclerosis by spinal transplantation","volume":"7","author":"Hefferan","year":"2012","journal-title":"PLoS One"},{"key":"10.1016\/bs.pmch.2018.12.001_bb0610","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1097\/01.tp.0000235532.00920.7a","article-title":"Human neural stem cell grafts ameliorate motor neuron disease in SOD-1 transgenic rats","volume":"82","author":"Xu","year":"2006","journal-title":"Transplantation"},{"key":"10.1016\/bs.pmch.2018.12.001_bb0615","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1080\/08977190902814855","article-title":"Stem cells: comprehensive treatments for amyotrophic lateral sclerosis in conjunction with growth factor delivery","volume":"27","author":"Lunn","year":"2009","journal-title":"Growth Factors"},{"key":"10.1016\/bs.pmch.2018.12.001_bb0620","doi-asserted-by":"crossref","first-page":"933","DOI":"10.1006\/nbdi.2001.0443","article-title":"Histological evidence of protein aggregation in mutant SOD1 transgenic mice and in amyotrophic lateral sclerosis neural tissues","volume":"8","author":"Watanabe","year":"2001","journal-title":"Neurobiol Dis"},{"key":"10.1016\/bs.pmch.2018.12.001_bb0625","doi-asserted-by":"crossref","first-page":"1188","DOI":"10.1111\/j.1471-4159.2010.06683.x","article-title":"Intracerebroventricular infusion of monoclonal antibody or its derived Fab fragment against misfolded forms of SOD1 mutant delays mortality in a mouse model of ALS","volume":"113","author":"Gros-Louis","year":"2010","journal-title":"J Neurochem"},{"key":"10.1016\/bs.pmch.2018.12.001_bb0630","doi-asserted-by":"crossref","first-page":"1044","DOI":"10.1097\/NEN.0b013e3181f4a90a","article-title":"Induction of protective immunity by vaccination with wild-type apo superoxide dismutase 1 in mutant SOD1 transgenic mice","volume":"69","author":"Takeuchi","year":"2010","journal-title":"J Neuropathol Exp Neurol"},{"key":"10.1016\/bs.pmch.2018.12.001_bb0635","doi-asserted-by":"crossref","first-page":"1099","DOI":"10.1517\/17460441.2015.1067197","article-title":"A retrospective review of the progress in amyotrophic lateral sclerosis drug discovery over the last decade and a look at the latest strategies","volume":"10","author":"DeLoach","year":"2015","journal-title":"Expert Opin Drug Discovery"},{"key":"10.1016\/bs.pmch.2018.12.001_bb0640","doi-asserted-by":"crossref","first-page":"903","DOI":"10.1016\/j.ejmech.2016.06.017","article-title":"Therapeutic progress in amyotrophic lateral sclerosis-beginning to learning","volume":"121","author":"Kumar","year":"2016","journal-title":"Eur J Med Chem"},{"key":"10.1016\/bs.pmch.2018.12.001_bb0645","doi-asserted-by":"crossref","first-page":"1083","DOI":"10.1016\/S1474-4422(14)70222-4","article-title":"Efficacy and safety of ceftriaxone for amyotrophic lateral sclerosis: results of a multi-stage, randomised, double-blind, placebo-controlled, phase 3 study merit","volume":"13","author":"Cudkowicz","year":"2015","journal-title":"Lancet Neurol"},{"key":"10.1016\/bs.pmch.2018.12.001_bb0650","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1007\/s13311-015-0341-2","article-title":"Clinical trial designs in amyotrophic lateral sclerosis: does one design fit all?","volume":"12","author":"Nicholson","year":"2015","journal-title":"Neurotherapeutics"},{"key":"10.1016\/bs.pmch.2018.12.001_bb0655","doi-asserted-by":"crossref","first-page":"3583","DOI":"10.2174\/0929867321666140601162710","article-title":"Potential therapeutic drugs and methods for the treatment of amyotrophic lateral sclerosis","volume":"21","author":"Yacila","year":"2014","journal-title":"Curr Med Chem"},{"key":"10.1016\/bs.pmch.2018.12.001_bb0665","first-page":"1","article-title":"Bromocriptine mesylate attenuates amyotrophic lateral sclerosis: a phase 2a, randomized, double-blind, placebo-controlled research in Japanese patients","volume":"11","author":"Nagata","year":"2016","journal-title":"PLoS One"},{"key":"10.1016\/bs.pmch.2018.12.001_bb0670","doi-asserted-by":"crossref","first-page":"9090","DOI":"10.1073\/pnas.93.17.9090","article-title":"Caffeic acid phenethyl ester is a potent and specific inhibitor of activation of nuclear transcription factor NF-kappa B","volume":"93","author":"Natarajan","year":"1996","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/bs.pmch.2018.12.001_bb0675","doi-asserted-by":"crossref","first-page":"3304","DOI":"10.1161\/STROKEAHA.114.005835","article-title":"Phase II trial of the sigma-1 receptor agonist cutamesine (SA4503) for recovery enhancement after acute ischemic stroke","volume":"45","author":"Urfer","year":"2014","journal-title":"Stroke"},{"key":"10.1016\/bs.pmch.2018.12.001_bb0680","series-title":"Diazoxide for use in the treatment of a central nervous system (CNS) autoimmune demyelinating disease","author":"Parrilla","year":"2011"},{"key":"10.1016\/bs.pmch.2018.12.001_bb0685","first-page":"5","article-title":"The interplay between metabolic homeostasis and neurodegeneration: insights into the neurometabolic nature of amyotrophic lateral sclerosis","volume":"4","author":"Ngo","year":"2015","journal-title":"Cell Regen (Lond)"},{"key":"10.1016\/bs.pmch.2018.12.001_bb0690","doi-asserted-by":"crossref","first-page":"2376","DOI":"10.1111\/j.1460-9568.2005.04431.x","article-title":"Memantine prolongs survival in an amyotrophic lateral sclerosis mouse model","volume":"22","author":"Wang","year":"2005","journal-title":"Eur J Neurosci"},{"key":"10.1016\/bs.pmch.2018.12.001_bb0695","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1006\/nbdi.2002.0487","article-title":"Minocycline slows disease progression in a mouse model of amyotrophic lateral sclerosis","volume":"10","author":"Kriz","year":"2002","journal-title":"Neurobiol Dis"},{"key":"10.1016\/bs.pmch.2018.12.001_bb0700","series-title":"MNTF peptides and compositions and methods of use","author":"Ko","year":"2007"},{"key":"10.1016\/bs.pmch.2018.12.001_bb0705","doi-asserted-by":"crossref","first-page":"345","DOI":"10.3390\/ph3020345","article-title":"Olesoxime (TRO19622): a novel mitochondrial-targeted neuroprotective compound","volume":"3","author":"Bordet","year":"2010","journal-title":"Pharmaceuticals"},{"key":"10.1016\/bs.pmch.2018.12.001_bb0710","doi-asserted-by":"crossref","first-page":"83","DOI":"10.2147\/DDDT.S112723","article-title":"Analysis of pramipexole dose\u2014response relationships in Parkinson's disease","volume":"11","author":"Wang","year":"2017","journal-title":"Drug Des Devel Ther"},{"key":"10.1016\/bs.pmch.2018.12.001_bb0715","doi-asserted-by":"crossref","first-page":"162e6","DOI":"10.1016\/j.clinthera.2015.10.010","article-title":"Efficacy of pramipexole for the treatment of primary restless leg syndrome: a systematic review and meta-analysis of randomized clinical trials","volume":"38","author":"Liu","year":"2016","journal-title":"Clin Ther"},{"key":"10.1016\/bs.pmch.2018.12.001_bb0720","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1371\/journal.pone.0091608","article-title":"Dexpramipexole is ineffective in two models of ALS related neurodegeneration","volume":"9","author":"Vieira","year":"2014","journal-title":"PLoS One"},{"key":"10.1016\/bs.pmch.2018.12.001_bb0725","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1038\/nature02544","article-title":"VEGF delivery with retrogradely transported lentivector prolongs survival in a mouse ALS model","volume":"27","author":"Azzouz","year":"2004","journal-title":"Nature"}],"container-title":["Progress in Medicinal Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0079646818300158?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0079646818300158?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,7,15]],"date-time":"2024-07-15T13:48:38Z","timestamp":1721051318000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0079646818300158"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019]]},"ISBN":["9780444642776"],"references-count":143,"URL":"https:\/\/doi.org\/10.1016\/bs.pmch.2018.12.001","relation":{},"ISSN":["0079-6468"],"issn-type":[{"value":"0079-6468","type":"print"}],"subject":[],"published":{"date-parts":[[2019]]}}}